Document Detail


Effect of intraperitoneal and intravenous administration of cholecystokinin-8 and apolipoprotein AIV on intestinal lymphatic CCK-8 and apo AIV concentration.
MedLine Citation:
PMID:  19020287     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CCK and apolipoprotein AIV (apo AIV) are gastrointestinal satiety signals whose synthesis and secretion by the gut are stimulated by fat absorption. Intraperitoneally administered CCK-8 is more potent in suppressing food intake than a similar dose administered intravenously, but the reason for this disparity is unclear. In contrast, both intravenous and intraperitoneally administered apo AIV are equally as potent in inhibiting food intake. When we compared the lymphatic concentration of CCK-8 and apo AIV, we found that neither intraperitoneally nor intravenously administered CCK-8 or apo AIV altered lymphatic flow rate. Interestingly, intraperitoneal administration of CCK-8 produced a significantly higher lymphatic concentration at 15 min than did intravenous administration. Intraperitoneal injection of apo AIV also yielded a higher lymphatic concentration at 30 min than did intravenous administration. Intraperitoneal administration of CCK-8 and apo AIV also resulted in a much longer period of elevated CCK-8 and apo AIV peptide concentration in lymph than intravenous administration. Furthermore, enzymatic activity of dipeptidyl peptidase IV (DPPIV) and aminopeptidase was higher in plasma than in lymph during fasting, and so, satiation peptides, such as CCK-8 and apo AIV in the lymph, are protected from degradation by the significantly lower DPPIV and aminopeptidase activity levels in lymph than in plasma. Therefore, the higher potency of intraperitoneally administered CCK-8 compared with intravenously administered CCK-8 in inhibiting food intake may be explained by both its higher concentration in lymph and the prolonged duration of its presence in the lamina propria.
Authors:
Chun-Min Lo; Min Xu; Qing Yang; Shuqin Zheng; Katherine M Carey; Matthew R Tubb; W Sean Davidson; Min Liu; Stephen C Woods; Patrick Tso
Related Documents :
8924037 - Baclofen pretreatment attenuates the suppressant effect of intraperitoneal administrati...
15713687 - Enterostatin decreases postprandial pancreatic ucp2 mrna levels and increases plasma in...
11739447 - Effect of exogenous cholecystokinin (cck)-8 on food intake and plasma cck, leptin, and ...
7381777 - The effects of alimentary infusions of glucose, amino acids, or neutral fat on meal siz...
17455437 - Discrepancy between satisfaction with mastication, food acceptability, and masticatory ...
15920927 - Increasing haccp awareness: a training intervention for caterers.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2008-11-19
Journal Detail:
Title:  American journal of physiology. Regulatory, integrative and comparative physiology     Volume:  296     ISSN:  0363-6119     ISO Abbreviation:  Am. J. Physiol. Regul. Integr. Comp. Physiol.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-30     Completed Date:  2009-02-06     Revised Date:  2013-06-04    
Medline Journal Info:
Nlm Unique ID:  100901230     Medline TA:  Am J Physiol Regul Integr Comp Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  R43-50     Citation Subset:  IM    
Affiliation:
Cincinnati Obesity Research Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45237, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aminopeptidases / blood
Animals
Apolipoproteins A / administration & dosage*,  metabolism
Appetite Depressants / administration & dosage*,  metabolism
Cholecystokinin / administration & dosage*,  metabolism
Dipeptidyl Peptidase 4 / blood
Dose-Response Relationship, Drug
Eating / drug effects*
Injections, Intraperitoneal
Injections, Intravenous
Intestines / drug effects*,  metabolism
Lymph / drug effects*,  enzymology
Male
Peptide Fragments / administration & dosage*,  metabolism
Rats
Rats, Sprague-Dawley
Recombinant Proteins / administration & dosage
Time Factors
Grant Support
ID/Acronym/Agency:
DK 17844/DK/NIDDK NIH HHS; DK 56390/DK/NIDDK NIH HHS; DK 56910/DK/NIDDK NIH HHS; DK 70992/DK/NIDDK NIH HHS; DK38180/DK/NIDDK NIH HHS; HL082734/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Apolipoproteins A; 0/Appetite Depressants; 0/Peptide Fragments; 0/Recombinant Proteins; 0/apolipoprotein A-IV; 0/cholecystokinin 8; 9011-97-6/Cholecystokinin; EC 3.4.11.-/Aminopeptidases; EC 3.4.14.5/Dipeptidyl Peptidase 4
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chronic intermittent hypoxia impairs heart rate responses to AMPA and NMDA and induces loss of gluta...
Next Document:  Cardiac damage after lesions of the nucleus tractus solitarii.